Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 24:10:458.
doi: 10.1186/1471-2407-10-458.

Molecular alterations in key-regulator genes among patients with T4 breast carcinoma

Affiliations

Molecular alterations in key-regulator genes among patients with T4 breast carcinoma

Bruno Massidda et al. BMC Cancer. .

Abstract

Background: Prognostic factors in patients who are diagnosed with T4 breast carcinomas are widely awaited. We here evaluated the clinical role of some molecular alterations involved in tumorigenesis in a well-characterized cohort of T4 breast cancer patients with a long follow-up period.

Methods: A consecutive series of 53 patients with T4 breast carcinoma was enrolled between 1992 and 2001 in Sardinia, and observed up for a median of 125 months. Archival paraffin-embedded tissue sections were used for immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses, in order to assess alterations in expression levels of survivin, p53, and pERK1-2 proteins as well as in amplification of CyclinD1 and h-prune genes. The Kaplan-Meier and Cox regression methods were used for survival assessment and statistical analysis.

Results: Overall, patients carrying increased expression of pERK1-2 (p = 0.027) and survivin (p = 0.008) proteins as well as amplification of h-prune gene (p = 0.045) presented a statistically-significant poorer overall survival in comparison with cases found negative for such alterations. After multivariate analysis, the pathological response to primary chemotherapy and the survivin overexpression in primary carcinoma represented the main parameters with a role as independent prognostic factors in our series.

Conclusions: Although retrospective, our study identified some molecular parameters with a significant impact on prediction of the response to therapy or prognosis among T4 breast cancer patients. Further large prospective studies are needed in order to validate the use of such markers for the management of these patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunohistochemistry and FISH analysis. (Up-middle) Typical examples of T4 breast carcinoma tissue sections positive (left) or negative (right) for p53, pERK1-2, and survivin protein expression. (Bottom) Typical examples of double-colour FISH results. Nuclei extracted from paraffin-embedded tissues after hybridization with probes specific for cyclinD1 or h-prune loci (red signals) and control chromosome centromeres (green signals).
Figure 2
Figure 2
Comparison between molecular markers and survivals among T4 breast cancer patients. (A) Overall survival curves based on the Kaplan-Meier method. Statistical comparison between observed and predicted survival data for each subset of patients [with (+) or without (-) alterations in expression of p53, pERK1-2 and survivin proteins or in copy number of h-prune and cyclinD1 genes) is reported. (B) Median disease-free and overall survivals (DFS and OS, respectively), expressed in months, for each subset of patients.

Similar articles

Cited by

References

    1. Sobin L, Wittekind C, (eds) TNM classification of malignant tumors. 6. John Wiley & Sons, New York; 2002.
    1. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36. doi: 10.1200/JCO.2002.02.026. - DOI - PubMed
    1. Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, Singletary SE, Theriault RL, Hortobagyi GN, Hunt KK, Buchholz TA. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003;21:3244–8. doi: 10.1200/JCO.2003.03.052. - DOI - PubMed
    1. Subramaniam DS, Isaacs C. Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol. 2005;6:147–159. doi: 10.1007/s11864-005-0022-1. - DOI - PubMed
    1. Hayes DF. Prognostic and predictive factors revisited. Breast. 2005;14:493–499. doi: 10.1016/j.breast.2005.08.023. - DOI - PubMed

Publication types

MeSH terms